866-997-4948(US-Canada Toll Free)

Bladder Cancer Global Clinical Trials Review, H2, 2017

Published By :

GlobalData

Published Date : Dec 2017

Category :

Pharmaceutical

No. of Pages : 609 Pages

Bladder Cancer Global Clinical Trials Review, H2, 2017

Summary

GlobalData's clinical trial report, Bladder Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Bladder Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Bladder Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Bladder Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Bladder Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Bladder Cancer Therapeutics Clinical Trials 28
Prominent Drugs 29
Latest Clinical Trials News on Bladder Cancer 30
Dec 08, 2017: Researchers Discover Resistance Mechanism To Checkpoint Inhibitors And How To Reverse It 30
Dec 08, 2017: Landmark Blue Light Cystoscopy with Cysview study is published in the Journal of Urology 30
Nov 15, 2017: BioCanCell Announces Updated Results from the Phase 2 Clinical Trial of BC-819 and BCG in Patients with Bladder Cancer 31
Nov 11, 2017: First Data for NKTR-214 in Combination with OPDIVO (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 31
Nov 10, 2017: Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting 33
Oct 30, 2017: Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy 33
Oct 23, 2017: BLC With Cysview/Hexvix Real World Data Presented at the Socit Internationale Durologie 2017 Annual Meeting 34
Oct 02, 2017: Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-343 34
Sep 12, 2017: Oncology Research: New Opportunities for Menarini and OBT 34
Clinical Trial Profile Snapshots 36
Appendix 606
Abbreviations 606
Definitions 606
Research Methodology 607
Secondary Research 607
About GlobalData 608
Contact Us 608
Disclaimer 608
Source 609

List of Tables
Bladder Cancer Therapeutics, Global, Clinical Trials by Region, 2017* 7
Bladder Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Bladder Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Bladder Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
Bladder Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
Bladder Cancer Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
Bladder Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 13
Bladder Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14
Proportion of Bladder Cancer to Oncology Clinical Trials, G7 Countries (%), 2017* 15
Bladder Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Bladder Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Bladder Cancer to Oncology Clinical Trials, E7 Countries (%), 2017* 18
Bladder Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
Bladder Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
Bladder Cancer Therapeutics, Global, Clinical Trials by Phase, 2017* 21
Bladder Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
Bladder Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
Bladder Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
Bladder Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
Bladder Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
Bladder Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
Bladder Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
Bladder Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29

List of Figures
Bladder Cancer Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Bladder Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Bladder Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Bladder Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 10
Bladder Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
Bladder Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12
Bladder Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 13
Bladder Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 14
Proportion of Bladder Cancer to Oncology Clinical Trials, G7 Countries (%), 2017* 15
Bladder Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Bladder Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Bladder Cancer to Oncology Clinical Trials, E7 Countries (%), 2017* 18
Bladder Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
Bladder Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
Bladder Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2017* 21
Bladder Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 22
Bladder Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
Bladder Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
Bladder Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
Bladder Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 26
Bladder Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
Bladder Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
Bladder Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29
GlobalData Methodology 607

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *